Trading of VistaGen Therapeutics was halted at 07:55 AM EST due to "News Pending". NASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $0.23 -0.53 (-70.26%) Closing price 04:00 PM EasternExtended Trading$0.23 +0.01 (+3.10%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$0.20▼$0.2450-Day Range$0.23▼$0.7652-Week Range$0.20▼$5.14Volume44.00 million shsAverage Volume1.09 million shsMarket Capitalization$9.27 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingReduce Company Overview VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingVistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialVistaGen Therapeutics has a consensus price target of $0.95, representing about 320.4% upside from its current price of $0.23.Amount of Analyst CoverageVistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.32) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.28% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 2.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently decreased by 15.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.93 News SentimentVistaGen Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for VistaGen Therapeutics this week, compared to 5 articles on an average week.Search Interest3 people have searched for VTGN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.85% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesVistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder TranscriptJune 30 at 3:01 PM | seekingalpha.comVistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummetJune 30 at 1:52 PM | reuters.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.June 30 at 1:00 AM | Chaikin Analytics (Ad)VistaGen Therapeutics (VTGN) to Post Earnings on WednesdayJune 24, 2026 | americanbankingnews.comVistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term GrowthJune 17, 2026 | tipranks.comVistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateJune 15, 2026 | businesswire.comVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderJune 9, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmJune 1, 2026 | prnewswire.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $0.6619 at the beginning of the year. Since then, VTGN shares have decreased by 65.9% and is now trading at $0.2260. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Monday, June, 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The firm earned $0.38 million during the quarter, compared to analysts' expectations of $0.40 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 133.02% and a negative net margin of 5,487.01%. When did VistaGen Therapeutics' stock split? Shares of VistaGen Therapeutics reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings6/15/2026Today6/30/2026Study update6/30/2026Next Earnings (Estimated)8/06/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 VTGN's financial health is in the Red zone, according to TradeSmith. VTGN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year Founded1998Price Target and Rating Average Price Target for VistaGen Therapeutics$0.95 High Price Target$1.00 Low Price Target$0.90 Potential Upside/Downside+320.4%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net Margins-5,487.01% Pretax Margin-5,490.78% Return on Equity-133.02% Return on Assets-105.79% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$1.27 million Price / Sales7.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.25Miscellaneous Outstanding Shares41,030,000Free Float39,863,000Market Cap$9.27 million OptionableOptionable Beta0.31 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:VTGN) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredForget the million-dollar nest egg — you only need THIS muchNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
